Insulin detemir causes increased symptom awareness during hypoglycaemia compared to human insulin

Diabetes, Obesity and Metabolism

Volumn 11, Issue 11, 2009, Pages 1017-1026

  Tschritter, O ^a   Schafer S A ^a   Klett, J ^a   Pfafflin A ^a   Haring H U ^a   Hennige, A M ^a   Fritsche, A ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Clinical trial; Insulin analogues; Insulin therapy

Indexed keywords

ADRENALIN; FATTY ACID; GLUCAGON; GLUCOSE; GROWTH HORMONE; HYDROCORTISONE; INSULIN DETEMIR; LACTIC ACID; NEUTRAL INSULIN; NORADRENALIN;

ADULT; ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE RESPONSE; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SWEATING; VOLUNTEER;

ADULT; BLOOD GLUCOSE; COGNITION; CROSS-OVER STUDIES; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 70350143228     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01085.x     Document Type: Article

References (29)

1. Jonassen I, Havelund S, Ribel U. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004, 21:1498-1504.
2. Kurtzhals P, Havelund S, Jonassen I, Markussen J. Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. J Pharm Sci 1997, 86:3365-1368.
3. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J Obes Relat Metab Disord 2004, 28(Suppl. 2):S23-S28.
4. Kurtzhals P, Schäffer L, Sørensen A. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000, 49:999-1005.
5. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Ribel U, Markussen J. Albumin binding and time action of acylated insulins in various species. J Pharm Sci 1996, 85:304-308.
6. Vague P, Selam JL, Skeie S. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003, 26:590-596.
7. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007, 9:290-299.
8. Kolendorf K, Ross GP, Pavlic-Renar I. Insulin detemir lowers the risk of hypoglycemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. Diabet Med 2006, 23:729-735.
9. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006, 29:1269-1274.
10. Jacobs MA, Salobir B, Popp-Snijders C, Ader H, Heine RJ. Counterregulatory hormone responses and symptoms during hypoglycemia induced by porcine, human regular insulin, and Lys(B28), Pro(B29) human insulin analogue (insulin Lispro) in healthy male volunteers. Diabet Med 1997, 14:248-257.
11. McCrimmon RJ, Frier BM. Symptomatic and physiological responses to hypoglycemia induced by human soluble insulin and the analogue Lispro human insulin. Diabet Med 1997, 14:929-936.
12. Frier BM, Ewing FM, Lindholm A, Hylleberg B, Kanc K. Symptomatic and counterregulatory hormonal responses to acute hypoglycemia induced by insulin aspart and soluble human insulin in Type 1 diabetes. Diabetes Metab Res Rev 2000, 16:262-268.
13. Dagogo-Jack S, Askari H, Morrill B, Lehner LL, Kim B, Sha X. Physiological responses during hypoglycemia induced by regular human insulin or a novel human analogue, insulin glargine. Diabetes Obes Metab 2000, 2:373-383.
14. Heller SR, Amiel SA, Evans ML, Kong MF, Macdonald IA, Peacey SR. Does insulin lispro preserve the physiological defences to hypoglycemia during intensive insulin therapy with a conventional basal bolus regimen?. Diabetes Obes Metab 2002, 4:106-112.
15. Chapman TM, Perry CM. Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 2004, 64:2577-2595.
16. Galassetti P, Davis SN. Effects of insulin per se on neuroendocrine and metabolic counter-regulatory responses to hypoglycemia. Clin Sci (Lond) 2000, 99:351-362.
17. Hennige AM, Sartorius T, Tschritter O. Tissue selectivity of insulin detemir action in vivo. Diabetologia 2006, 49:1274-1282.
18. Fisher SJ, Bruning JC, Lannon S, Kahn CR. Insulin signaling in the central nervous system is critical for the normal sympathoadrenal response to hypoglycemia. Diabetes 2005, 54:1447-1451.
19. Tschritter O, Hennige AM, Preissl H. Cerebrocortical beta activity in overweight humans respond to insulin detemir. PLoS ONE 2007, 2:e1196.
20. Hepburn DA, Deary IJ, Frier BM, Patrick AW, Quinn JD, Fisher BM. Symptoms of acute insulin-induced hypoglycemia in humans with and without IDDM. Factor-analysis approach. Diabetes Care 1991, 14:949-957.
21. Fritsche A, Stefan N, Haring H, Gerich J, Stumvoll M. Avoidance of hypoglycemia restores hypoglycemia awareness by increasing beta-adrenergic sensitivity in type 1 diabetes. Ann Intern Med 2001, 134:729-736.
22. Towler DA, Havlin CE, Craft S, Cryer P. Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes 1993, 42:1791-1798.
23. Tschritter O, Preissl H, Hennige AM. The cerebrocortical response to hyperinsulinemia is reduced in overweight humans: a magnetoencephalographic study. Proc Natl Acad Sci USA 2006, 103:12103-12108.
24. Kern W, Peters A, Fruehwald-Schultes B, Deininger E, Born J, Fehm HL. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology 2001, 74:270-280.
25. Hallschmid M, Schultes B, Marshall L. Transcortical direct current potential shift reflects immediate signaling of systemic insulin to the human brain. Diabetes 2004, 53:2202-2208.
26. Kerr D, Reza M, Smith N, Leatherdale BA. Importance of insulin in subjective, cognitive, and hormonal responses to hypoglycemia in patients with IDDM. Diabetes 1991, 40:1057-1062.
27. Lingenfelser T, Overkamp D, Renn W. Insulin-associated modulation of neuroendocrine counterregulation, hypoglycemia perception, and cerebral function in insulin-dependent diabetes mellitus: evidence for an intrinsic effect of insulin on the central nervous system. J Clin Endocrinol Metab 1996, 81:1197-1205.
28. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991, 87:2246-2252.
29. Rossetti P, Porcellati F, Busciantella Ricci N. Different brain responses to hypoglycemia induced by equipotent doses of the long-acting insulin analog detemir and human regular insulin in humans. Diabetes 2008, 57:746-756.